3 Penny Stocks Insiders Are Buying

Although Eurozone economy grew 0.3% on quarter during the last three months of 2021, in-line with flash estimates, there were a few notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Pluristem Therapeutics

  • The Trade: Pluristem Therapeutics Inc. PSTI Director Zami Aberman acquired a total of 80,616 shares at an average price of $1.80. To acquire these shares, it cost $145.11 thousand.
  • What’s Happening: Pluristem Therapeutics and Tnuva, last month, announced a collaboration to establish a cultured food platform.
  • What Pluristem Therapeutics Does: Pluristem Therapeutics Inc is a US-based company that acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions.

Sensei Biotherapeutics

  • The Trade: Sensei Biotherapeutics, Inc. SNSE Director James Peyer acquired a total of 17,500 shares at an average price of $4.45. The insider spent around $77.9 thousand to buy those shares.
  • What’s Happening: Sensei Biotherapeutics, last month, named Erin Colgan as CFO.
  • What Sensei Biotherapeutics Does: Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer.

Also check this: Insiders Buy Around $112M Of 3 Stocks

IMARA

  • The Trade: IMARA Inc. IMRA Director David Mott acquired a total of 31,826 shares at an average price of $1.23. To acquire these shares, it cost $39.25 thousand.
  • What’s Happening: Last month, the FDA signed off Imara’s investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved ejection fraction (HFpEF).
  • What IMARA Does: Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsPenny StocksEurozoneInsider TradesMarketsTrading IdeasInsider Buying
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!